^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PI3Kβ inhibitor

    Related drugs:
    Apply
    PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (NCT03218826)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    09/24/2018
    Primary completion :
    07/25/2022
    Completion :
    10/03/2025
    HER-2 • ER • PTEN • PIK3CB
    |
    ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    docetaxel • AZD8186
    Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss (NCT03131908)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/13/2025
    Initiation :
    07/17/2017
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    PTEN
    |
    PTEN loss
    |
    Keytruda (pembrolizumab) • GSK2636771
    Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) (NCT04439149)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/09/2024
    Initiation :
    02/25/2016
    Primary completion :
    11/30/2024
    Completion :
    11/30/2024
    PTEN
    |
    PTEN expression
    |
    GSK2636771
    Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) (NCT04439188)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/08/2024
    Initiation :
    02/25/2016
    Primary completion :
    11/30/2024
    Completion :
    11/30/2024
    PTEN
    |
    PTEN loss
    |
    GSK2636771
    Biomarker-Integrated Umbrella, Advanced Gastric Cancer (NCT02951091)
    Phase 2
    Yonsei University
    Active, not recruiting
    Last update posted :
    07/20/2022
    Initiation :
    01/01/2016
    Primary completion :
    12/01/2021
    Completion :
    12/01/2022
    PD-L1
    |
    Opdivo (nivolumab) • GSK2636771
    PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma (NCT02615730)
    Phase 1/2
    Yonsei University
    Completed
    Last update posted :
    04/22/2021
    Initiation :
    02/01/2016
    Primary completion :
    03/31/2021
    Completion :
    03/31/2021
    PTEN • PIK3CB
    |
    paclitaxel • GSK2636771
    Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer (NCT02215096)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    10/22/2020
    Initiation :
    11/13/2014
    Primary completion :
    10/03/2019
    Completion :
    10/03/2019
    PTEN
    |
    Xtandi (enzalutamide) • GSK2636771
    AZD8186 First Time In Patient Ascending Dose Study (NCT01884285)
    Phase 1
    AstraZeneca
    Completed
    Last update posted :
    05/29/2020
    Initiation :
    07/09/2013
    Primary completion :
    03/31/2019
    Completion :
    02/07/2020
    HER-2 • ER • PGR • PTEN • PIK3CB
    |
    HER-2 negative • PIK3CB mutation
    |
    abiraterone acetate • AZD8186 • vistusertib (AZD2014)
    AZD8186 and Paclitaxel in Advanced Gastric Cancer (NCT04001569)
    Phase 1/2
    Seoul National University Bundang Hospital
    Recruiting
    Last update posted :
    06/28/2019
    Initiation :
    05/14/2019
    Primary completion :
    12/31/2021
    Completion :
    12/31/2022
    PTEN • PIK3CB
    |
    PTEN deletion
    |
    paclitaxel • AZD8186
    A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency (NCT01458067)
    Phase 1/2
    GlaxoSmithKline
    Completed
    Last update posted :
    07/24/2018
    Initiation :
    11/10/2011
    Primary completion :
    11/12/2015
    Completion :
    02/25/2016
    HER-2 • PGR • PTEN
    |
    HER-2 negative
    |
    GSK2636771